Fluticasone furoate/umeclidinium/vilanterol: Ph III CAPTAIN started

GlaxoSmithKline began the double-blind, international Phase III CAPTAIN trial to compare once-daily fluticasone furoate/umeclidinium/vilanterol delivered in GSK’s Ellipta dry powder inhaler vs. once-daily inhaled Relvar/Breo Ellipta fluticasone furoate/vilanterol in about 2,250 patients with inadequately controlled asthma. Patients will receive 100/31.25/25, 100/62.5/25, 200/31.25/25 or 200/62.5/25 μg fluticasone furoate/umeclidinium/vilanterol; or 100/25 or 200/25 μg fluticasone furoate/vilanterol...